|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L04AX05
|
|
gptkbp:bioavailability
|
~81%
|
|
gptkbp:brand
|
gptkb:Esbriet
gptkb:Pirespa
|
|
gptkbp:CASNumber
|
gptkb:53179-13-8
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
severe liver impairment
severe kidney impairment
|
|
gptkbp:discoveredBy
|
gptkb:Mitsubishi_Tanabe_Pharma
|
|
gptkbp:eliminationHalfLife
|
2.4 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
gptkbp:hasMolecularFormula
|
C12H11NO
|
|
gptkbp:hasPatent
|
gptkb:US_Patent_5,616,600
|
|
gptkbp:hasSMILES
|
O=C1NC=CC=C1C2=CC=CC=C2
|
|
gptkbp:hasUNII
|
P3G4227T27
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pirfenidone
|
|
gptkbp:IUPACName
|
gptkb:5-methyl-1-phenyl-2(1H)-pyridone
|
|
gptkbp:KEGGID
|
D08323
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
anti-inflammatory
antifibrotic
|
|
gptkbp:meltingPoint
|
109-110°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
185.22 g/mol
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:DB04951
gptkb:CHEMBL1201197
40632
37057
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
fatigue
rash
photosensitivity
|
|
gptkbp:synonym
|
gptkb:Esbriet
gptkb:AMR69
gptkb:Pirespa
gptkb:S-7701
|
|
gptkbp:usedFor
|
idiopathic pulmonary fibrosis
|
|
gptkbp:bfsParent
|
gptkb:Esbriet
|
|
gptkbp:bfsLayer
|
7
|